Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Chemoradiotherapy in Locally Advanced Cervical Cancer
NCT03830866Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2019
- Primary completion
- Jan 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 15
01
Overview
A Phase 3 trial of durvalumab in Cervical Cancer (CC), sponsored by AstraZeneca. Started Feb 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03830866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830866.